Pneumonia caused by Coronavirus 2019, COVID19. Coronavirus infection, unspecified
Conditions
Interventions
Intervention 1: Intervention group: Patients in this group are treated with 100 mg oral thalidomide tablets manufactured by Ibn Sina Company on a daily basis for up to fourteen days. These drugs are a
Sponsors
Esfahan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 18-75 year old men and 50-75 year old women admitted in hospital Percentage of oxygen saturation at the time of admission: 89-85% (provided it is modified with Nazal auxiliary oxygen to more or equal to 90%) or oxygen saturation percentage of 90-93% and the number of breaths per minute more or equal to 30 Clinical manifestations associated with COVID-19 pneumonia with positive PCR test or HR-CT scan
Exclusion criteria
Exclusion criteria: Previous Chronic lung disease Multi-organ failure at admission
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time to reach clinical recovery. Timepoint: Daily visit in the hospital every 8 hours by the physician. Method of measurement: Pulse oximetery device. | — |
Secondary
| Measure | Time frame |
|---|---|
| 28 days survival rate. Timepoint: Weekly up to 4 weeks from the time of hospitalization to 4 weeks after discharge. Method of measurement: Telephone call. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSamane Pourajam
Esfahan University of Medical Sciences
Outcome results
None listed